# Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

> **NCT04170153** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 161 (actual)

## Conditions studied

- Metastatic or Locally Advanced Unresectable Solid Tumors

## Interventions

- **DRUG:** M1774
- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT04170153
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-20
- **Primary completion:** 2026-07-30
- **Final completion:** 2026-07-30
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04170153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04170153, "Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04170153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*